Craniotomy procedures are usually required to remove brain tumours, treat an aneurysm, relieve intracranial pressure, or perform deep brain stimulation among a number of other treatments. Credit: Shutterstock / Wasan Tita

US-based bone adhesive company RevBio has received a $2.4 million grant from the National Institutes of Health (NIH) to drive the company’s completion of a 20-patient trial of its bone adhesive biomaterial dubbed Tetranite.

Designed to fixate cranial flaps and enable bone fusion following craniotomy procedures associated with brain surgery, Tetranite previously received US Food and Drug Administration (FDA) clearance for the 20-patient pilot trial designed to examine the material’s safety and efficacy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The two-year Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disease and Stroke (NINDS) will fund the trial which is taking place at Semmes Murphey Clinic in Memphis, Tennessee, and Brigham and Women’s Hospital in Boston, Massachusetts, with first five patients having already been successfully enrolled.

Speaking after the results from one patient who underwent cranial flap surgery using Tetranite, Madison Michael, co-director of cranial base surgery for the Methodist Brain and Spine Institute and investigator for the study, said: “All radiographic follow-up images show continued adhesion of the bone flap to the surrounding skull with no complications.”

Craniotomy procedures are usually required to remove brain tumours, treat an aneurysm, relieve intracranial pressure, or perform deep brain stimulation among a number of other treatments.

See Also:

Market research carried out by GlobalData found that the US bone grafts and substitutes market will generate $2.2bn in 2030 in the US, increasing at a compound annual growth rate (CAGR) of 3.2% from $1.6bn in 2020.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Timothy Smith, director of the Computational Neuroscience Outcomes Center, added: “Advanced techniques have led to longer-term survival rates for patients who undergo brain surgery.

“Having just been through a very traumatic experience, improved bone healing through the revascularisation of the flap and better cosmetic outcomes are important for patient self-esteem and for helping them move on with their lives”.

Elsewhere in the field of bone grafts and substitutes, regenerative health company LifeNet Health has announced the launch of its newest bone allograft designed in collaboration with healthcare giant Johnson & Johnson MedTech. Meanwhile, Biocomposites is set to commence distribution of its NanoBone product range across the UK.